|
|
Article: Tigris Licenses Aminoflavone Prodrug For Cancer From NIH.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Less than a week after licensing several small-molecule, preclinical oncology compounds from major institutions, Tigris Pharmaceuticals Inc. picked up rights to another - this time a Phase I aminoflavone (AF) prodrug for cancer from the National Institutes of Health.
The NIH drug, AFP-464, is undergoing two Phase I studies in patients with solid tumors. Under the terms of the license, Tigris would provide development-based undisclosed milestone payments and royalties.
Preclinical work suggests AFP-464 is converted to metabolites that bind covalently to DNA, resulting in p53 activation and apoptosis. In the National Cancer ...